SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 27, 2001
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
VIRGINIA 0-30739 54-1972729
- ---------------------------------------------------------------------------------------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation) Identification No.)
800 East Leigh Street, Richmond, VA 23219
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (804) 828-6893
ITEM 5. OTHER EVENTS
On February 27, 2001, Insmed Incorporated issued a press release
announcing the results in two key Phase II clinical trials, one in obese
women with polycystic ovarian syndrome (PCOS) and one in dyslipidemia in
non-diabetic subjects, for its lead oral insulin sensitizer, INS-1.
Insmed also announced in the press release that Insmed's management team
will host a conference call on Wednesday, February 28 at 9:00 a.m. EST
to discuss these results. The dial-in number is 800-289-0493 (domestic)
or 913-981-5510 (international). The reference code is 433360. A replay
of the call will be available from 12:00 p.m. EST, Wednesday, February
28 through 12:00 p.m. EST, Wednesday, March 7, 2001. The replay dial-in
number is 888-203-1112 (domestic) or 719-457-0820 (international). A
copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. The press release was also posted on
Insmed's website on February 27, 2001.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibit
99.1 Press Release dated February 27, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INSMED INCORPORATED
Date: February 28, 2001 By: /s/ Michael D. Baer
-------------------------
Michael D. Baer
Chief Financial Officer
INSMED INCORPORATED
INDEX TO EXHIBITS
Exhibit Number
99.1 Press Release dated February 27, 2001.